top of page
Search

Doctor explains: A new clinical trial finds low-dose naltrexone reduces Long COVID fatigue, but is no better than placebo

Nov 2
6 min read

Doctor reviewing research on low-dose naltrexone for Long COVID and ME/CFS.

Low-dose naltrexone (LDN) has attracted considerable interest among people living with Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia. Some patients report improvements in fatigue, pain, sleep and brain fog, and the medication has increasingly been discussed as a possible treatment option.

A new randomised controlled trial has produced an important finding: fatigue improved in people taking LDN, but the improvement was not significantly greater than in people taking placebo.

What does this mean for patients already taking LDN, those considering treatment, and the future of ME/CFS research? As an ME/CFS specialist, I believe it is important to examine the results carefully, without dismissing patients' experiences or making claims that the evidence cannot support.

What did the new LDN trial find?

The study, Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial, was published on medRxiv in October 2026. It is available here.

The researchers conducted a randomised, double-blind, placebo-controlled trial involving 160 adults in Canada who had developed persistent symptoms consistent with ME/CFS following COVID-19.

Participants were randomly assigned to receive either LDN or a placebo for 16 weeks. The LDN dose started at 1 mg daily and was increased to a maximum of 4.5 mg daily as tolerated.

The main outcome was fatigue severity. The researchers also assessed pain, overall ME/CFS symptoms, daily step counts and quality of life.

The key findings were:

  • Fatigue: Fatigue improved during the study, including among participants taking LDN. However, the improvement was not significantly greater than in the placebo group.

  • Pain: LDN did not demonstrate a significant advantage over placebo.

  • Overall symptoms: The study found no significant advantage for LDN in the measured ME/CFS-related symptoms.

  • Physical activity: Daily step counts did not show a significant advantage for LDN.

  • Quality of life: No significant benefit over placebo was demonstrated.

The central finding is therefore not that fatigue cannot improve during LDN treatment. Rather, the trial did not establish that LDN itself produced a greater improvement than the placebo treatment.

This distinction matters. When people participate in a clinical trial, their symptoms may improve for several reasons, including natural fluctuations in illness, changes in daily routines, the effects of clinical support and the placebo response. A placebo-controlled trial helps researchers determine whether a treatment offers an additional benefit beyond these effects.

The study is a preprint, meaning it has not yet undergone peer review. Its findings should therefore be interpreted with appropriate caution.

Why is this important for ME/CFS and Long COVID?

LDN has become popular partly because there are relatively few established treatments that directly address the underlying illness in ME/CFS.

People living with these conditions may experience profound exhaustion, unrefreshing sleep, cognitive difficulties and post-exertional malaise (PEM). PEM is the worsening of symptoms following physical, mental or emotional activity that might previously have been manageable. The deterioration can be delayed and may last days or longer.

The overlap between ME/CFS and Long COVID has encouraged researchers to investigate whether treatments developed or used for one condition might also help the other.

Before this trial, interest in LDN was supported by biological theories, clinical experience and small observational studies. Some patients reported feeling better after starting treatment.

The new findings add an important piece of evidence. Although fatigue improved during the trial, LDN did not outperform placebo. Consequently, the improvement observed in the LDN group cannot confidently be attributed to a specific effect of the medication.

This does not mean the improvement was imaginary. It means that the trial could not establish that LDN was responsible for a greater improvement than would have occurred with placebo.

The results suggest that LDN should not currently be regarded as an established, evidence-based treatment for post-COVID fatigue on the basis of demonstrated superiority over placebo.

Importantly, the study investigated people with post-COVID fatigue syndrome. It does not establish whether LDN has the same effects in every subgroup of people with ME/CFS, in people with fibromyalgia, or in patients with different symptom patterns.

Does this mean LDN never helps?

Not necessarily. It means that this trial did not demonstrate an overall benefit compared with placebo in the population studied.

A trial result cannot automatically tell us whether a particular subgroup might respond differently. However, it would be premature to claim that particular patients benefit when reliable evidence identifying such subgroups is lacking.

Equally, an individual's improvement while taking a medication is a genuine experience, even when research has not established that the medication caused that improvement.

The appropriate conclusion is neither that LDN definitely works nor that it is impossible for anyone to benefit. Rather, its effectiveness remains uncertain, and the new trial provides an important reason to reconsider how confidently it is recommended.

Further research would need to determine whether any clinically meaningful benefit exists, which outcomes might improve, and whether particular patient characteristics predict a response.

What should patients do if they are taking LDN?

If you are already taking LDN, do not stop or change your medication solely because of a research paper. Discuss the findings with your prescribing clinician and review whether you have experienced a meaningful, sustained improvement.

It may help to consider several questions:

  • Has your day-to-day functioning improved?

  • Have fatigue, pain, sleep or brain fog changed in a consistent way?

  • Are you experiencing side effects?

  • Is there a clear treatment goal that can be reviewed over time?

  • Are the benefits sufficient to justify the cost, inconvenience and uncertainty?

LDN is generally prescribed off-label for conditions such as ME/CFS and fibromyalgia. It is not an established, licensed treatment for ME/CFS itself. Naltrexone can also interfere with opioid medicines, so its use requires appropriate medical supervision.

If you are considering starting treatment, a discussion with a suitably qualified clinician can help you weigh the uncertain evidence against possible risks and alternatives.

What management strategies remain important?

There is no single treatment that works for everyone with ME/CFS. Good care begins with understanding the person's symptoms, functional limitations, associated conditions and priorities.

One important element is post-exertional malaise (PEM) management. Activity should be adjusted to avoid repeatedly exceeding the individual's available energy. Pacing, including micro-pacing for people with severe ME, can help reduce avoidable overexertion. It is not a guarantee against symptom deterioration, and activity should not be increased according to a fixed schedule regardless of symptoms.

A clinical assessment may also consider sleep dysfunction, orthostatic intolerance, postural orthostatic tachycardia syndrome (POTS), pain, medication effects and other conditions that may contribute to symptoms or require separate treatment.

There is a need for further research into ME/CFS therapy, including treatments targeting biological mechanisms, but proposed treatments should be distinguished from those supported by convincing clinical evidence. Claims about functional medicine for chronic fatigue, mitochondrial support or other emerging approaches also need careful assessment.

An ME/CFS specialist can help patients understand these options without assuming that every intervention is appropriate or safe for every individual.

How can an online ME/CFS doctor help?

A specialist consultation can help clarify the diagnosis, review previous investigations, assess potential alternative explanations for fatigue and develop a management plan that reflects the patient's circumstances.

A private ME/CFS clinic online may be particularly useful for people who have difficulty travelling or who need a more focused assessment of persistent symptoms. An online consultation cannot replace investigations or physical examinations when these are clinically necessary, but it can provide a structured opportunity to discuss symptoms, previous results and treatment choices.

At UK ME/CFS Specialist, consultations can address ME/CFS, Long COVID, fibromyalgia and other post-viral conditions. Depending on the clinical question, an assessment may include discussion of ME/CFS testing, available research, symptom management and the limitations of current evidence.

The service may also be relevant to people seeking a Long COVID fatigue clinic, a fibromyalgia specialist online or a post viral fatigue doctor.

The central message from the new LDN trial is that fatigue can improve during treatment, but improvement during treatment is not the same as proving that a medication works better than placebo. People living with ME/CFS and Long COVID deserve treatments that improve their lives, alongside honest explanations of what research has—and has not—shown.

Further information and consultations

You can also explore the clinic's ME/CFS and related conditions information and read more about ME/CFS research, ME/CFS testing and ME/CFS therapy on the UK ME/CFS Specialist blog.

If you would like to discuss whether your symptoms fit ME/CFS, fibromyalgia, Long COVID or another post-viral condition, you can book an online specialist consultation or learn more about Prof. Dmitry Pshezhetskiy and his clinical and research work.

Prof. Dmitry Pshezhetskiy, MBBS, PhD, MRCGP

GMC 7494518 — Registered Medical Practitioner (GP)

Medical Disclaimer: The information provided in this article is for general educational and informational purposes only and does not constitute personalised medical advice, formal diagnosis or treatment planning. Reading this content or communicating via this website does not establish a doctor-patient relationship with Prof. Dmitry Pshezhetskiy. ME/CFS affects every individual differently; strategies discussed may not be suitable or safe for your specific health situation. Always consult your GP, specialist healthcare team or NHS 111 regarding your personal medical concerns. In a medical emergency, please dial 999 or visit your nearest Emergency Department immediately. For a full disclaimer, see Medical Disclaimer & Terms of Use in Terms and Conditions on the policies page.

If you would like specialist assessment, learn more about our online consultations.

 
 
 

Comments


bottom of page